<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01004042</url>
  </required_header>
  <id_info>
    <org_study_id>09-CBED09-02</org_study_id>
    <nct_id>NCT01004042</nct_id>
  </id_info>
  <brief_title>Quality of Life and Self-esteem After Botox® Injections in Depressed and Non-depressed Patients</brief_title>
  <official_title>Evaluation of Quality of Life and Self-esteem After Botulinum Toxin type-a (Botox®) Injections in Depressed and Non-depressed Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brazilan Center for Studies in Dermatology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brazilan Center for Studies in Dermatology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the alterations in quality of life and&#xD;
      self-esteem after BOTOX® injections in the glabella in depressed and non-depressed patients.&#xD;
&#xD;
      The secondary objective of this study are:&#xD;
&#xD;
        -  to assess wrinkles improvement&#xD;
&#xD;
        -  to evaluate depressive symptoms using Beck Depression Inventory before and after Botox®&#xD;
           injections.&#xD;
&#xD;
        -  to elucidate that depression is not a contraindication for botulinum toxin injections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of two groups: one with diagnosis of depression (diagnostic criteria from&#xD;
      DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0) and&#xD;
      other without diagnosis of depression.&#xD;
&#xD;
      Subjects with depression will be part of group 1. They must be using a therapeutic dose of&#xD;
      antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.&#xD;
&#xD;
      Subjects with no diagnosis of depression will be part of group 2. Subjects included in the&#xD;
      study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A&#xD;
      (BOTOX®, Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5&#xD;
      points of glabellar area as the treatment.&#xD;
&#xD;
      Four visits will be scheduled. Visit 0 (baseline), Visit 1 (intervention), visit 2 (4 weeks),&#xD;
      visit 3 (8 weeks) visit 4 (12 weeks).&#xD;
&#xD;
      The scales for the assessment of depressive symptoms, Beck Depression Inventory (BDI), will&#xD;
      be applied at visits 1,2,3,4; WHOQOL BREF will be applied at baseline visit and 4.&#xD;
&#xD;
      Rosenberg Self-Esteem Scale will be applied in all visits. Photographs will be taken as well&#xD;
      as the dermatological evaluation of the wrinkles and folds will be assessed using a 4-points&#xD;
      validated Severity Wrinkles Scale, and psychiatric evaluation as well, in both groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rosenberg Self-Esteem Scale</measure>
    <time_frame>Baseline, Day 1 (intervention), Week 4, Week 8, Week 12</time_frame>
    <description>Measure of self esteem for research purposes.&#xD;
Ten questions graded from 0 to 3 as described below:&#xD;
Questions 1, 3, 4, 7, 10&#xD;
0 - Totally agree&#xD;
- Agree&#xD;
- Disagree&#xD;
- Totally disagree&#xD;
Questions 2, 5, 6, 8, 9&#xD;
3 - Totally agree 2 - Agree&#xD;
1 - Disagree 0 - Totally disagree&#xD;
The scale ranges from 0-30. Scores between 15 and 25 are within normal range; scores below 15 suggest low self-esteem.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>Baseline, Day 1 (intervention), Week 4, Week 8, Week 12</time_frame>
    <description>BDI is a 21-question multiple-choice self-report inventory, one of the most widely used psychometric tests for measuring the severity of depression. Each question is graded from 0 to 3.&#xD;
0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WHOQOL-BREF</measure>
    <time_frame>Baseline, Day 1 (intervention), Week 4, Week 8, Week 12</time_frame>
    <description>The WHOQOL-BREF is a scale for the quality of life assessment developed by the World Health Organization. It is composed by 26 questions graded from 1 to 5.&#xD;
Scoring:&#xD;
1 to 2.9 - needs improvement 3 to 3.9 - regular 4 to 4.9 - good 5 - very good&#xD;
Question 1 asks about the individual's overall perception of quality of life. Results refer to question 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wrinkle Severity Scale (WSS) at Rest</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>The injection of botulinum toxin type A causes muscle paralysis, reducing facial lines. Wrinkle scales are used to grade the muscular effects of botulinum toxin.&#xD;
The WSS is a 4-point validated scale for forehead lines:&#xD;
0 - None&#xD;
- Mild&#xD;
- Moderate&#xD;
- Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wrinkle Severity Scale (WSS) at Maximum Contraction</measure>
    <time_frame>Baseline, Day 1 (intervention), Week 4, Week 8, Week 12</time_frame>
    <description>The injection of botulinum toxin type A causes muscle paralysis, reducing facial lines. Wrinkle scales are used to grade the muscular effects of botulinum toxin.&#xD;
The WSS is a 4-point validated scale for forehead lines:&#xD;
0 - None&#xD;
- Mild&#xD;
- Moderate&#xD;
- Severe</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Depression</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Depressed subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diagnosis of depression (diagnostic criteria from DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0.)They must be using a therapeutic dose of antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non Depressed subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with no diagnosis of depression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <description>Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.</description>
    <arm_group_label>Depressed subjects</arm_group_label>
    <arm_group_label>Non Depressed subjects</arm_group_label>
    <other_name>Botox®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female subjects,aged between 25 to 60 years;&#xD;
&#xD;
          2. Subjects diagnosed as having major depression according to the criteria of DSM-IV,&#xD;
             MINI International Neuropsychiatric Interview (MINI Brazilian version 5.0.0);&#xD;
&#xD;
          3. Subjects who are being administered a therapeutic dose of an approved, prescribed&#xD;
             antidepressant medication (pattern doses of the literature), and have been using&#xD;
             mentioned medication at a stable therapeutic dose for at least three months prior to&#xD;
             the randomization visit;&#xD;
&#xD;
          4. Subjects with mild (1), moderate (2) or severe (3) glabellar frown lines while at rest&#xD;
             according the Severity Wrinkles Scales;&#xD;
&#xD;
          5. Female subjects of childbearing age that present a negative urine pregnancy test and&#xD;
             are using an effective contraceptive method;&#xD;
&#xD;
          6. Subjects who had never received botulinum toxin A previously;&#xD;
&#xD;
          7. Subjects agreeing to take part of the study, after being fully informed of the purpose&#xD;
             and the nature of the investigation and after having signed the informed consent form;&#xD;
&#xD;
          8. Subjects who will be available throughout the duration of the study;&#xD;
&#xD;
          9. Subjects with sufficient schooling and awareness to enable them to cooperate to the&#xD;
             degree required by this protocol;&#xD;
&#xD;
         10. Subjects with Critical appreciation preserved, attested by their assistant&#xD;
             psychiatrist (for group1);&#xD;
&#xD;
         11. Subjects who reside with other family members who assume co-responsibility in the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects whose medical history and physical examination present clinical pathology, as&#xD;
             myasthenia gravis, Eaton-Lambert Syndrome, neoplasm, muscular diseases, motor neuron&#xD;
             diseases, systemic autoimmune or neurological diseases;&#xD;
&#xD;
          2. Pregnant or women in breastfeeding, or women planning to become pregnant&#xD;
&#xD;
          3. Subjects with suicide risk;&#xD;
&#xD;
          4. Subjects addicted to alcohol or illegal drugs within the last 6 months;&#xD;
&#xD;
          5. Subjects using amino glycoside and penicillamine antibiotics, quinine and Ca2+ channel&#xD;
             blockers;&#xD;
&#xD;
          6. Subjects using medications that, in the opinion of the investigator may cause&#xD;
             depression, such as beta-blockers, oral corticosteroids and interferon;&#xD;
&#xD;
          7. Subjects who, in the opinion of the investigator, may potentially require psychiatric&#xD;
             hospitalization during the course of the study;&#xD;
&#xD;
          8. Subjects with inflammation or active infection in the area to be injected;&#xD;
&#xD;
          9. Subjects with a history of non-adherence to medical treatment, or who demonstrate&#xD;
             unwillingness to adhere to the study protocol;&#xD;
&#xD;
         10. The presence of any additional active DSM-IV Axis I diagnosis, or mental retardation;&#xD;
&#xD;
         11. History of psychiatric hospitalization within the past three years.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doris M Hexsel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brazilian Center For Studies in Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brazilian Center for Studies in Dermatology</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90570 040</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 28, 2009</study_first_submitted>
  <study_first_submitted_qc>October 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2009</study_first_posted>
  <results_first_submitted>December 14, 2020</results_first_submitted>
  <results_first_submitted_qc>January 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 26, 2021</results_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brazilan Center for Studies in Dermatology</investigator_affiliation>
    <investigator_full_name>Doris Hexsel</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Botulinum toxin</keyword>
  <keyword>Glabella</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Self-steem</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Depressed Subjects</title>
          <description>Diagnosis of depression (diagnostic criteria from DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0.)They must be using a therapeutic dose of antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.&#xD;
Botulinum Toxin Type A: Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.</description>
        </group>
        <group group_id="P2">
          <title>Non Depressed Subjects</title>
          <description>Subjects with no diagnosis of depression&#xD;
Botulinum Toxin Type A: Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Depressed Subjects</title>
          <description>Diagnosis of depression (diagnostic criteria from DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0.)They must be using a therapeutic dose of antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.&#xD;
Botulinum Toxin Type A: Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.</description>
        </group>
        <group group_id="B2">
          <title>Non Depressed Subjects</title>
          <description>Subjects with no diagnosis of depression&#xD;
Botulinum Toxin Type A: Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="7"/>
                    <measurement group_id="B2" value="48" spread="7"/>
                    <measurement group_id="B3" value="49" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Measure Description: Phototype I - Pale white skin, blue/green eyes, blond/red hair; Always burns, does not tan Phototype II - Fair skin, blue eyes; Burns easily, tans poorly Phototype III - Darker white skin; Tans after initial burn Phototype IV - Light brown skin; Burns minimally, tans easily Phototype V - Brown skin; Rarely burns, tans darkly easily Phototype VI - Dark brown or black skin; Never burns, always tans darkly</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Fitzpatrick Skin Phototype I</title>
              <category_list>
                <category>
                  <title>Phototype I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Phototype II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Phototype III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Phototype IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Phototype V</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Phototype VI</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Married or steady relationship</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Single</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Divorced</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>College</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>College (not completed)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High School</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Middle School</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rosenberg Self-Esteem Scale</title>
        <description>Measure of self esteem for research purposes.&#xD;
Ten questions graded from 0 to 3 as described below:&#xD;
Questions 1, 3, 4, 7, 10&#xD;
0 - Totally agree&#xD;
- Agree&#xD;
- Disagree&#xD;
- Totally disagree&#xD;
Questions 2, 5, 6, 8, 9&#xD;
3 - Totally agree 2 - Agree&#xD;
1 - Disagree 0 - Totally disagree&#xD;
The scale ranges from 0-30. Scores between 15 and 25 are within normal range; scores below 15 suggest low self-esteem.</description>
        <time_frame>Baseline, Day 1 (intervention), Week 4, Week 8, Week 12</time_frame>
        <population>per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Depressed Subjects</title>
            <description>Diagnosis of depression (diagnostic criteria from DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0.)They must be using a therapeutic dose of antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.&#xD;
Botulinum Toxin Type A: Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.</description>
          </group>
          <group group_id="O2">
            <title>Non Depressed Subjects</title>
            <description>Subjects with no diagnosis of depression&#xD;
Botulinum Toxin Type A: Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Rosenberg Self-Esteem Scale</title>
          <description>Measure of self esteem for research purposes.&#xD;
Ten questions graded from 0 to 3 as described below:&#xD;
Questions 1, 3, 4, 7, 10&#xD;
0 - Totally agree&#xD;
- Agree&#xD;
- Disagree&#xD;
- Totally disagree&#xD;
Questions 2, 5, 6, 8, 9&#xD;
3 - Totally agree 2 - Agree&#xD;
1 - Disagree 0 - Totally disagree&#xD;
The scale ranges from 0-30. Scores between 15 and 25 are within normal range; scores below 15 suggest low self-esteem.</description>
          <population>per protocol.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="5.3"/>
                    <measurement group_id="O2" value="24.6" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (intervention)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="5.0"/>
                    <measurement group_id="O2" value="23.3" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" spread="5.8"/>
                    <measurement group_id="O2" value="23.5" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" spread="5.9"/>
                    <measurement group_id="O2" value="24.4" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" spread="6.5"/>
                    <measurement group_id="O2" value="24.2" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Beck Depression Inventory (BDI)</title>
        <description>BDI is a 21-question multiple-choice self-report inventory, one of the most widely used psychometric tests for measuring the severity of depression. Each question is graded from 0 to 3.&#xD;
0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression.</description>
        <time_frame>Baseline, Day 1 (intervention), Week 4, Week 8, Week 12</time_frame>
        <population>Per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Depressed Subjects</title>
            <description>Diagnosis of depression (diagnostic criteria from DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0.)They must be using a therapeutic dose of antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.&#xD;
Botulinum Toxin Type A: Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.</description>
          </group>
          <group group_id="O2">
            <title>Non Depressed Subjects</title>
            <description>Subjects with no diagnosis of depression&#xD;
Botulinum Toxin Type A: Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory (BDI)</title>
          <description>BDI is a 21-question multiple-choice self-report inventory, one of the most widely used psychometric tests for measuring the severity of depression. Each question is graded from 0 to 3.&#xD;
0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression.</description>
          <population>Per protocol.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" spread="5.2"/>
                    <measurement group_id="O2" value="6.7" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (intervention)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" spread="8.8"/>
                    <measurement group_id="O2" value="5.8" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" spread="7.9"/>
                    <measurement group_id="O2" value="5.3" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="9.9"/>
                    <measurement group_id="O2" value="4.5" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="7.9"/>
                    <measurement group_id="O2" value="4.0" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WHOQOL-BREF</title>
        <description>The WHOQOL-BREF is a scale for the quality of life assessment developed by the World Health Organization. It is composed by 26 questions graded from 1 to 5.&#xD;
Scoring:&#xD;
1 to 2.9 - needs improvement 3 to 3.9 - regular 4 to 4.9 - good 5 - very good&#xD;
Question 1 asks about the individual's overall perception of quality of life. Results refer to question 1.</description>
        <time_frame>Baseline, Day 1 (intervention), Week 4, Week 8, Week 12</time_frame>
        <population>Per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Depressed Subjects</title>
            <description>Diagnosis of depression (diagnostic criteria from DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0.)They must be using a therapeutic dose of antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.&#xD;
Botulinum Toxin Type A: Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.</description>
          </group>
          <group group_id="O2">
            <title>Non Depressed Subjects</title>
            <description>Subjects with no diagnosis of depression&#xD;
Botulinum Toxin Type A: Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>WHOQOL-BREF</title>
          <description>The WHOQOL-BREF is a scale for the quality of life assessment developed by the World Health Organization. It is composed by 26 questions graded from 1 to 5.&#xD;
Scoring:&#xD;
1 to 2.9 - needs improvement 3 to 3.9 - regular 4 to 4.9 - good 5 - very good&#xD;
Question 1 asks about the individual's overall perception of quality of life. Results refer to question 1.</description>
          <population>Per protocol.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="0.77"/>
                    <measurement group_id="O2" value="3.9" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (intervention)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="0.85"/>
                    <measurement group_id="O2" value="4.0" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="0.60"/>
                    <measurement group_id="O2" value="4.1" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="0.89"/>
                    <measurement group_id="O2" value="4.1" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="0.81"/>
                    <measurement group_id="O2" value="4.1" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wrinkle Severity Scale (WSS) at Rest</title>
        <description>The injection of botulinum toxin type A causes muscle paralysis, reducing facial lines. Wrinkle scales are used to grade the muscular effects of botulinum toxin.&#xD;
The WSS is a 4-point validated scale for forehead lines:&#xD;
0 - None&#xD;
- Mild&#xD;
- Moderate&#xD;
- Severe</description>
        <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Depressed Subjects</title>
            <description>Diagnosis of depression (diagnostic criteria from DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0.)They must be using a therapeutic dose of antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.&#xD;
Botulinum Toxin Type A: Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.</description>
          </group>
          <group group_id="O2">
            <title>Non Depressed Subjects</title>
            <description>Subjects with no diagnosis of depression&#xD;
Botulinum Toxin Type A: Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Wrinkle Severity Scale (WSS) at Rest</title>
          <description>The injection of botulinum toxin type A causes muscle paralysis, reducing facial lines. Wrinkle scales are used to grade the muscular effects of botulinum toxin.&#xD;
The WSS is a 4-point validated scale for forehead lines:&#xD;
0 - None&#xD;
- Mild&#xD;
- Moderate&#xD;
- Severe</description>
          <population>Per protocol</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.76"/>
                    <measurement group_id="O2" value="1.5" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.61"/>
                    <measurement group_id="O2" value="0.5" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.62"/>
                    <measurement group_id="O2" value="0.4" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.62"/>
                    <measurement group_id="O2" value="0.7" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wrinkle Severity Scale (WSS) at Maximum Contraction</title>
        <description>The injection of botulinum toxin type A causes muscle paralysis, reducing facial lines. Wrinkle scales are used to grade the muscular effects of botulinum toxin.&#xD;
The WSS is a 4-point validated scale for forehead lines:&#xD;
0 - None&#xD;
- Mild&#xD;
- Moderate&#xD;
- Severe</description>
        <time_frame>Baseline, Day 1 (intervention), Week 4, Week 8, Week 12</time_frame>
        <population>Per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Depressed Subjects</title>
            <description>Diagnosis of depression (diagnostic criteria from DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0.)They must be using a therapeutic dose of antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.&#xD;
Botulinum Toxin Type A: Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.</description>
          </group>
          <group group_id="O2">
            <title>Non Depressed Subjects</title>
            <description>Subjects with no diagnosis of depression&#xD;
Botulinum Toxin Type A: Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Wrinkle Severity Scale (WSS) at Maximum Contraction</title>
          <description>The injection of botulinum toxin type A causes muscle paralysis, reducing facial lines. Wrinkle scales are used to grade the muscular effects of botulinum toxin.&#xD;
The WSS is a 4-point validated scale for forehead lines:&#xD;
0 - None&#xD;
- Mild&#xD;
- Moderate&#xD;
- Severe</description>
          <population>Per protocol.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.69"/>
                    <measurement group_id="O2" value="2.7" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.64"/>
                    <measurement group_id="O2" value="1.2" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.80"/>
                    <measurement group_id="O2" value="1.2" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.70"/>
                    <measurement group_id="O2" value="1.7" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Depressed Subjects</title>
          <description>Diagnosis of depression (diagnostic criteria from DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0.)They must be using a therapeutic dose of antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.&#xD;
Botulinum Toxin Type A: Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.</description>
        </group>
        <group group_id="E2">
          <title>Non Depressed Subjects</title>
          <description>Subjects with no diagnosis of depression&#xD;
Botulinum Toxin Type A: Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <description>Edema on the nose and infraorbital region. Patient with past history of latex allergy.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Mild eyebrow ptosis</sub_title>
                <description>Mild ptosis in medial third of the right eyebrow</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Doris Hexsel</name_or_title>
      <organization>Brazilian Center for Studies in Dermatology</organization>
      <phone>+55 51 30262633</phone>
      <email>cientifico@cbed.org.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

